55.96
price down icon1.04%   -0.59
after-market アフターアワーズ: 55.95 -0.010 -0.02%
loading
前日終値:
$56.55
開ける:
$56.925
24時間の取引高:
2.58M
Relative Volume:
0.96
時価総額:
$9.25B
収益:
$1.06B
当期純損益:
$-326.58M
株価収益率:
-26.62
EPS:
-2.1022
ネットキャッシュフロー:
$-977.73M
1週間 パフォーマンス:
+5.68%
1か月 パフォーマンス:
-31.07%
6か月 パフォーマンス:
-31.87%
1年 パフォーマンス:
+32.47%
1日の値動き範囲:
Value
$55.79
$57.09
1週間の範囲:
Value
$50.01
$57.48
52週間の値動き範囲:
Value
$40.03
$86.74

Ionis Pharmaceuticals Inc Stock (IONS) Company Profile

Name
名前
Ionis Pharmaceuticals Inc
Name
セクター
Healthcare (1074)
Name
電話
(760) 931-9200
Name
住所
2855 GAZELLE COURT, CARLSBAD, CA
Name
職員
1,402
Name
Twitter
@ionispharma
Name
次回の収益日
2026-07-29
Name
最新のSEC提出書
Name
IONS's Discussions on Twitter

Compare IONS vs VRTX, REGN, ARGX, RVMD, ALNY

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
IONS icon
IONS
Ionis Pharmaceuticals Inc
55.96 9.35B 1.06B -326.58M -977.73M -2.1022
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
479.00 121.16B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
667.17 68.78B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
888.82 57.44B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
188.07 40.23B 742.00K -1.37B -1.07B -7.0731
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
278.40 36.28B 4.29B 577.22M 641.34M 4.2086

Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-04-21 開始されました Canaccord Genuity Buy
2026-04-10 再開されました Raymond James Outperform
2026-01-28 再開されました Barclays Overweight
2025-10-08 アップグレード JP Morgan Neutral → Overweight
2025-09-26 アップグレード Goldman Sell → Neutral
2025-09-03 アップグレード BMO Capital Markets Market Perform → Outperform
2025-07-31 アップグレード Morgan Stanley Equal-Weight → Overweight
2025-07-01 アップグレード Barclays Equal Weight → Overweight
2025-04-07 開始されました H.C. Wainwright Buy
2025-03-31 開始されました Redburn Atlantic Neutral
2024-08-02 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-07-24 アップグレード Leerink Partners Market Perform → Outperform
2024-07-16 再開されました Jefferies Buy
2024-06-14 アップグレード Bernstein Underperform → Mkt Perform
2024-04-10 アップグレード Wolfe Research Peer Perform → Outperform
2024-01-02 アップグレード BofA Securities Neutral → Buy
2023-10-23 アップグレード BofA Securities Underperform → Neutral
2023-09-29 開始されました Raymond James Strong Buy
2023-07-31 アップグレード Citigroup Neutral → Buy
2023-06-07 再開されました Piper Sandler Overweight
2023-05-04 アップグレード Citigroup Sell → Neutral
2023-03-21 開始されました Bernstein Underperform
2022-12-21 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-09-09 再開されました Morgan Stanley Overweight
2022-07-18 再開されました Oppenheimer Outperform
2022-03-31 再開されました Piper Sandler Overweight
2022-03-01 開始されました Citigroup Sell
2022-03-01 開始されました Guggenheim Buy
2022-02-01 ダウングレード BofA Securities Buy → Underperform
2021-12-14 アップグレード William Blair Mkt Perform → Outperform
2021-05-07 アップグレード UBS Sell → Neutral
2021-03-01 アップグレード Barclays Underweight → Equal Weight
2020-12-16 開始されました UBS Sell
2020-12-15 アップグレード Cowen Market Perform → Outperform
2020-09-14 再開されました JP Morgan Neutral
2020-09-02 開始されました The Benchmark Company Hold
2020-06-01 再開されました Oppenheimer Outperform
2020-05-13 開始されました RBC Capital Mkts Outperform
2020-03-05 開始されました Citigroup Buy
2019-12-13 開始されました Oppenheimer Outperform
2019-11-13 開始されました BofA/Merrill Buy
2019-11-07 ダウングレード Morgan Stanley Equal-Weight → Underweight
2019-09-10 アップグレード Bernstein Mkt Perform → Outperform
2018-08-08 繰り返されました Stifel Hold
2018-08-07 繰り返されました Stifel Hold
2018-05-08 ダウングレード Evercore ISI Outperform → In-line
2017-10-06 再開されました Goldman Sell
2017-08-17 開始されました Evercore ISI Outperform
2017-08-09 繰り返されました Stifel Hold
2017-03-10 ダウングレード Goldman Neutral → Sell
2016-12-28 繰り返されました BMO Capital Markets Outperform
2016-12-27 繰り返されました Leerink Partners Mkt Perform
すべてを表示

Ionis Pharmaceuticals Inc (IONS) 最新ニュース

pulisher
12:14 PM

Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceutica - The National Law Review

12:14 PM
pulisher
05:22 AM

Ionis Pharmaceuticals (IONS) Stock Analysis: Uncovering a Potential 62% Upside in the Biotech Sector - DirectorsTalk Interviews

05:22 AM
pulisher
Jul 25, 2026

Ionis Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:IONS - TradingView

Jul 25, 2026
pulisher
Jul 25, 2026

Ionis Pharmaceuticals, Inc. Revenue Breakdown – DUS:ISI - TradingView

Jul 25, 2026
pulisher
Jul 25, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmaceuticals, Inc. (IONS) And Encourages Investors to Connect - ACCESS Newswire

Jul 25, 2026
pulisher
Jul 24, 2026

Ionis Pharmaceuticals Inc (IONS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Ionis Pharmaceuticals Inc (IONS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

TradingKey - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Ionis Pharmaceuticals Inc (IONS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Ionis Pharmaceuticals Inc (IONS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Ionis Pharmaceuticals Inc (IONS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Ionis Pharmaceuticals Inc. (IONS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks

Jul 24, 2026
pulisher
Jul 24, 2026

IONS|Ionis Pharmaceuticals Inc|Price:56.550|Chg%:+0.680 - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Jul 24, 2026
pulisher
Jul 23, 2026

How Eplontersen’s Phase 3 Setback And Scrutiny At Ionis Pharmaceuticals (IONS) Has Changed Its Investment Story - Yahoo Finance

Jul 23, 2026
pulisher
Jul 23, 2026

Ionis stock trades steady as genetic medicine pipeline advances and revenue grows - Ad-hoc-news.de

Jul 23, 2026
pulisher
Jul 23, 2026

Ionis Pharmaceuticals (IONS) Misses A Key Trial Endpoint, Is The Valuation Now Too Harsh? - Yahoo Finance

Jul 23, 2026
pulisher
Jul 23, 2026

The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily

Jul 23, 2026
pulisher
Jul 23, 2026

Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23%HBSS - Morningstar

Jul 23, 2026
pulisher
Jul 23, 2026

Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $110 - Moomoo

Jul 23, 2026
pulisher
Jul 23, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc.IONS - PR Newswire

Jul 23, 2026
pulisher
Jul 23, 2026

Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or uniQure N.V. Stock? - AAII

Jul 23, 2026
pulisher
Jul 23, 2026

Canaccord reiterates Ionis stock rating on Tryngolza advantage By Investing.com - Investing.com Canada

Jul 23, 2026
pulisher
Jul 23, 2026

Ionis Pharmaceuticals Inc (IONS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 23, 2026
pulisher
Jul 22, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 22, 2026
pulisher
Jul 22, 2026

Arrowhead rises on phase III hypertriglyceridemia readout - BioWorld News

Jul 22, 2026
pulisher
Jul 22, 2026

Plozasiran Phase III Results Expand Cardiometabolic Use - AllSci

Jul 22, 2026
pulisher
Jul 22, 2026

Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug - BioPharma Dive

Jul 22, 2026
pulisher
Jul 22, 2026

Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data - Fierce Pharma

Jul 22, 2026
pulisher
Jul 22, 2026

Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug - BioSpace

Jul 22, 2026
pulisher
Jul 22, 2026

Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR) - Seeking Alpha

Jul 22, 2026
pulisher
Jul 22, 2026

Earnings Preview: Ionis Pharmaceuticals (IONS) Q2 Earnings Expected to Decline - Yahoo Finance

Jul 22, 2026
pulisher
Jul 22, 2026

Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug - Seeking Alpha

Jul 22, 2026
pulisher
Jul 21, 2026

Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Jul 21, 2026
pulisher
Jul 21, 2026

Ionis Pharmaceuticals, Inc. (IONS) Shows Oversold Potential with Low RSI - GuruFocus

Jul 21, 2026
pulisher
Jul 21, 2026

How does Biogen’s novel Alzheimer’s drug compare to approved drugs - MSN

Jul 21, 2026
pulisher
Jul 21, 2026

2026-07-21 | Ionis Pharmaceuticals, Inc. (IONS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:IONS | Press Release - Stockhouse

Jul 21, 2026
pulisher
Jul 21, 2026

Ionis Pharmaceuticals Stock Slides 39% With A 9-Day Losing Spree - Trefis

Jul 21, 2026
pulisher
Jul 21, 2026

Guggenheim cuts Ionis stock price target on Tryngolza sales outlook By Investing.com - Investing.com Canada

Jul 21, 2026
pulisher
Jul 21, 2026

Ionis Pharmaceuticals Stock Slides 39% Over 9 Straight Down Days - Trefis

Jul 21, 2026
pulisher
Jul 20, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire

Jul 20, 2026
pulisher
Jul 20, 2026

Bronstein, Gewirtz & Grossman, LLC Is Investigating Ionis Pharmac - The National Law Review

Jul 20, 2026
pulisher
Jul 20, 2026

Ionis Pharmaceuticals Stock Slides 37% Over 8 Straight Down Days - Trefis

Jul 20, 2026
pulisher
Jul 20, 2026

Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Leader with a 70.90% Potential Upside - DirectorsTalk Interviews

Jul 20, 2026
pulisher
Jul 20, 2026

Ionis Pharmaceuticals (IONS) Goldman Sachs 45th Annual Global Healthcare Conference summary - Quartr

Jul 20, 2026
pulisher
Jul 19, 2026

2026-07-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Ionis Pharmaceuticals, Inc. (IONS) and Encourages Stockholders to Learn More About the Investigation | NDAQ:IONS | Press Release - Stockhouse

Jul 19, 2026
pulisher
Jul 19, 2026

(IONS) Risk Channels and Responsive Allocation - Stock Traders Daily

Jul 19, 2026
pulisher
Jul 18, 2026

Ionis Pharmaceuticals (IONS) Proxy filing Summary - Quartr

Jul 18, 2026
pulisher
Jul 18, 2026

Bronstein, Gewirtz & Grossman, LLC Encourages Ionis Pharmaceuticals, Inc. (IONS) Investors to Inquire about Securities Investigation - ACCESS Newswire

Jul 18, 2026
pulisher
Jul 18, 2026

Cathie Wood Just Bet Big on This Biotech Stock - The Motley Fool

Jul 18, 2026
pulisher
Jul 17, 2026

Form 4 Ionis Pharmaceuticals Inc For: 17 July By Investing.com - Investing.com Nigeria

Jul 17, 2026

Ionis Pharmaceuticals Inc (IONS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$91.09
price up icon 1.97%
$118.87
price up icon 1.02%
$34.72
price down icon 0.83%
$58.73
price down icon 0.17%
ONC ONC
$325.90
price up icon 0.00%
$278.40
price up icon 2.44%
大文字化:     |  ボリューム (24 時間):